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The Effects of Puerarin on Rat 
Ventricular Myocytes and the 
Potential Mechanism
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Qinyi Wang1, Longmei He3, Lanxiang Ma4, Hua Zhang4, Li Zhang5, Hui Jiang6, Xiao Ke2 & 
Yuchun Gu1
Puerarin, a known isoflavone, is commonly found as a Chinese herb medicine. It is widely used in 
China to treat cardiac diseases such as angina, cardiac infarction and arrhythmia. However, its 
cardioprotective mechanism remains unclear. In this study, puerarin significantly prolonged ventricular 
action potential duration (APD) with a dosage dependent manner in the micromolar range on isolated 
rat ventricular myocytes. However, submicromolar puerarin had no effect on resting membrane 
potential (RMP), action potential amplitude (APA) and maximal velocity of depolarization (Vmax) of 
action potential. Only above the concentration of 10 mM, puerarin exhibited more aggressive effect 
on action potential, and shifted RMP to the positive direction. Millimolar concentrations of puerarin 
significantly inhibited inward rectified K+ channels in a dosage dependent manner, and exhibited bigger 
effects upon Kir2.1 vs Kir2.3 in transfected HEK293 cells. As low as micromolar range concentrations of 
puerarin significantly inhibited Kv7.1 and IKs. These inhibitory effects may due to the direct inhibition 
of puerarin upon channels not via the PKA-dependent pathway. These results provided direct preclinical 
evidence that puerarin prolonged APD via its inhibitory effect upon Kv7.1 and IKs, contributing to a 
better understanding the mechanism of puerarin cardioprotection in the treatment of cardiovascular 
diseases.
The kudzu root (Pueraria lobata) have been used as a Chinese herbal medicines to treat cardiovascular diseases 
for thousand years. Puerarin, a known isoflavone, was commonly found as an important component in the kudzu 
root. It is the 8-c-glucoside of daidzein1 and has been widely prescribed in clinic in China to treat cardiac diseases 
such as heart failure, ischemia, angina pectoris2,3, cardiac infarction and arrhythmia4–6. Previously, patients, diag-
nosised with arrhythmia and manifested as premature ventricular/atrial contraction and ventricular tachycardia, 
were enrolled in a randomized, double-blind and placebo-controlled trials7. Puerarin group received intravenous 
injection on day 1 (at a dose of 200 mg puerarin, and 20 ml of 50% glucose solution over a period of 10 minutes), 
and on days 2 through 7 (10 mg per kilogram per day in 500 ml of 5% glucose solution). Both the attack frequency 
and the disappearance time of arrhythmia in puerarin group were significantly reduced compared with placebo 
group. Puerarin was also applied in clinic to treat arrhythmia with the advantage of this long-lasting effect8.
However, the mechanism of this anti-arrhythmia effect of puerarin remains unclear and less study is performed 
to illustrate the detailed mechanism of puerarin effect on cardiac electrical signal transmission. Puerarin was 
previously found to inhibit phosphatidylinositol 3-kinase (PI3 K)/protein kinase B (Akt) and c-jun-NH2-kinase 
(JNK) signaling pathways to retard the progress of cardiac dependent NADPH oxidase activation and medi-
ated downstream redox-sensiutive-AP-1 signaling pathways to achieve its anti-hypertrophic effect9. Additionally, 
several studies revealed that puerarin antagonized ouabain-induced ventricular tachycardia in guinea pigs and 
chloroform/epinephrine-induced cardiac arrhythmias in rabbits10,11. Moreover, puerarin inhibited cardiac Na+ 
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channel by shifting the steady-state inactivation curve without alternation in the shape of the I-V curve of INa12. 
Puerarin was also suggested to target upon P2X(3) to block the nociceptive of pain transmission which closely 
related with complications after myocardial ischemic injury and cardiac arrhythmia13.
Therefore, in this study, we concentrate upon the effect of puerarin on cardiac action potential and related ion 
channels in ventricles.
Results
Puerarin significantly prolonged APD of rat ventricular Nmyocytes. Puerarin is known as an iso-
flavone (Fig. 1d) that is found in a number of plants and herbs such as the root of pueraria14. Puerarin at the con-
centrations of 100 μ M significantly prolonged APD of rat ventricular myocytes; whereas isoproterenol (10 nM) 
significantly shortened APD of rat ventricles, comparing with control (Fig. 1a,b). This prolonged APD was aug-
mented when different concentrations of puerarin was applied, exhibiting a dosage dependent manner (Fig. 1c). 
Statistically, puerarin (100 μ M) significantly prolonged APD50 from (71.8 ± 11.8) mS to (100.5 ± 14.1) mS and 
APD90 from (164.6 ± 21.4) mS to (221.6 ± 25.7) mS (Table 1); whereas RMP, APA and Vmax were not affected 
by application of puerarin. However, when 1 mM, 100 mM and 200 mM puerarin was applied, RMP was affected 
from − (80.1 ± 2.7) mV to − (75.3 ± 2.4) mV, − (74.7 ± 2.6) mV and − (73.5 ± 2.1) mV, respectively. The effect of 
the other dosages such as 10 μ M and 1 mM of puerarin on ventricular action potential was also summarized in 
Table 1.
The results above indicated that puerarin apparently affected the repolarization phase of action potential, 
which are majorly contributed by IKs (slow delayed rectified, constituted by KvLQT1/MinK), IKr (rapid delay 
rectified, constituted by HERG)15 and IK1 (inward rectified, constituted by Kir2.x). To avoid the interference elic-
ited by non-interested ion channels, suspected puerarin targeting ion channels such as inward rectified potassium 
channels, KvLQT1/Kv7.1 channels and IKs (KCNQ and KCNE) channels were therefore cloned and expressed in 
HEK cells16. The work below was performed in these expression systems.
Figure 1. Puerarin prolonged APD of rat ventricular myocytes. (a) Puerarin at the concentrations of 100 μ M 
significantly prolonged APD of rat ventricles; whereas isoproterenol at the concentrations of 10 nM significantly 
shortened APD of rat ventricles, in comparing with control. (b) Puerarin (100 μ M) significantly offseted the 
reduced effect of isoproterenol (10 nM) and extended APD of rat ventricles at the 50% and 90% measurement 
points by respectively. *P < 0.01, **P < 0.001 versus control. n = 5 each point. (c) Puerarin at the concentrations 
of 10 μ M, 100 μ M, 1 mM, 10 mM, 100 mM and 200 mM extended APD of rat ventricles, in comparing with 
control. The statistical results were shown in table1. (d) The molecular structural formula of puerarin.
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Puerarin at the concentration of milomolar range inhibited Kir 2.1 and Kir2.3 channels in a 
dosage dependent manner. The specificity of Kir2.1 was initially confirmed by its voltage-dependent Cs+ 
blockage17 and Ba2+ blockage (data not shown). The ramp voltage was a classic protocol to clearly observe the 
inward rectification of K+ current below its reverse potential18. Puerarin at the concentrations of 10 mM, 50 mM, 
100 mM, 200 mM significantly inhibited Kir2.1 currents illustrated by the ramp voltage protocol, respectively. 
This effect could be partly reversed by washing-off compound (Fig. 2a). While puerarin at low concentrations 
of 10 μ M, 10 μ M, 1 mM had little effect on Kir2.1 currents. Additionally, there was a concentration dependent 
inhibition by puerarin upon Kir 2.1. The maximal inhibitory effect was (53.11 ± 1.84) % and saturation dosage 
was 50 mM. Dosage curve was fitted with non-linear Hill. IC50 = 1.27 mM, Hill coefficient is 0.990 (n = 5 each 
point) (Fig. 2b).
Group RMP/mV APA/mV Vmax V/s APD50/ms APD90/ms
Control −80.1 ± 2.7 112.5 ± 6.3 226.9 ± 12.4 71.8 ± 11.8 164.6 ± 21.4
Puerarin ( mM)
 0.01 −80.5 ± 2.2 109.8 ± 8.5 217.5 ± 10.7 86.9 ± 10.7* 188.3 ± 11.5*
 0.1 −80.3 ± 1.6 114.2 ± 4.9 242.1 ± 13.8 100.5 ± 14.1# 221.6 ± 25.7#
 1 −79.7 ± 1.5 115.9 ± 6.2 236.1 ± 15.9 123.6 ± 25.4# 278.7 ± 28.2#
 10 −75.3 ± 2.4# 112.6 ± 4.7 238.4 ± 11.5 131.4 ± 19.6* 330.1 ± 22.3*
 100 −74.7 ± 2.6# 113.8 ± 5.1 240.6 ± 12.1 146.9 ± 21.8# 415.6 ± 28.4#
 200 −73.5 ± 2.1# 111.7 ± 5.6 237.8 ± 10.4 162.3 ± 23.5# 439.5 ± 29.6#
Table 1.  Effects of different concentrations of puerarin on action potential properties of rat ventricular 
myocytes. Note: RMP, resting membrane potential; APA, action potential amplitude; Vmax, maximal velocity 
of depolarization; APD50 and APD90, the APD at 50% and 90% repolarization. *P < 0.05, #P < 0.01 vs the control 
group, respectively.
Figure 2. Puerarin inhibited Kir2.1 and Kir2.3 channels in a dosage dependent manner. (a) Puerarin 
at the concentrations of 10 μ M, 100 μ M, 10 mM, 50 mM, 100 mM, 200 mM significantly inhibited Kir2.1 
currents illustrated by the ramp voltage protocol, respectively. This effect could be partly reversed by simple 
compound wash-off. (b) Concentration dependent inhibition by puerarin upon Kir2.1. The maximal inhibitory 
effect was (53.11 ± 1.84) % and saturation dosage was 50 mM. Dosage curve was fitted with non-linear Hill. 
IC50 = 1.27 mM, Hill coefficient is 0.990. n = 5 each point. (c) Puerarin at the concentrations of 10 μ M, 100 μ M, 
1 mM, 10 mM, 50 mM, 100 mM, 200 mM significantly inhibited Kir2.3 currents illustrated by the ramp voltage 
protocol, respectively. This effect could be partly reversed by simple compound wash-off. (d) Concentration 
dependent inhibition by puerarin upon Kir2.3. Dosage curve was fitted with non-linear Hill. IC50 = 129.4 mM, 
Hill coefficient is 0.984. n = 5 each point.
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Human Kir2.2 Kir2.3 and Kir2.1 (KCNJ12, KCNJ4 and KCNJ219–21, constitute human myocardial IKir. Kir2.3 
channels were expressed in HEK-293 cells to further clarify the effect of puerarin on Kir2. Puerarin at the con-
centrations of 10 mM, 50 mM, 100 mM, 200 mM significantly inhibited Kir2.3 currents illustrated by the ramp 
voltage protocol, respectively. This effect could also be reversed by washing-off compound (Fig. 2c). However, 
puerarin at low concentrations of 10 μ M, 100 μ M, 1 mM also had less effect on Kir2.3 currents. Additionally, a 
concentration dependent inhibition by puerarin upon Kir 2.3 was also shown in Fig. 2c. Dosage curve was fitted 
with non-linear Hill. IC50 = 129.4 mM, Hill coefficient was 0.984. n = 5 each point (Fig. 2d). However, it is noticed 
that the effective inhibitory dosage of puerarin is extremely high and it was rarely to use in clinic22.
Puerarin at the concentration of micromolar range inhibited Kv7.1 channels in a dosage 
dependent manner. Kv7.1 was assembled by KCNQ1, which is the α -subunit of a voltage-dependent potas-
sium channel. Co-assembly KCNQ1 with an auxiliary β subunit KCNE1 form IKs23. The biophysical properties 
of KCNQ1 was notably modified by KCNE1, including slowing activation and deactivation kinetics, increas-
ing unitary channel conductance, shifting the voltage dependence of activation to more negative potentials24. 
Abundant intracellular molecules and pathways, including cAMP, ATP, tyrosine kinases, protein kinase A (PKA) 
are reported to regulate Kv7.1/IKs25.
Because the tail current was one of the perspectives of Kv7.126, the specific protocol based on the voltage 
steps was majorly used in this study. Puerarin at the concentrations of 10 μ M, 100 μ M, 1 mM and 10 mM sig-
nificantly inhibited Kv7.1 currents, respectively (Fig. 3a). I-V curves summarized inhibitory effects of 10 μ M, 
100 μ M, 1 mM, 10 mM puerarin upon Kv7.1. This inhibitory effect could be reversed by washing-off compound 
(Fig. 3b). There was a concentration dependent inhibition by puerarin upon Kv7.1 at the both peak currents and 
tail currents (Fig. 3c). Dosage curve was fitted with non-linear Hill. IC50 = 36.01 μ M at the peak currents and 
IC50 = 39.77 μ M at the tail currents, Hill coefficient was 0.997. n = 6 each point.
Puerarin inhibited IKs channels in a dosage dependent manner. IKs currents were majorly mediated 
by channels composed of KCNQ and KCNE27. Puerarin at the concentrations of 10 μ M, 100 μ M, 1 mM and 10 mM 
significantly inhibited IKs currents, respectively (Fig. 4a). I-V curves summarized inhibitory effects of 10 μ M, 
100 μ M, 1 mM, 10 mM puerarin upon IKs. This inhibitory effect could be reversed by washing-off compound 
(Fig. 4b). A concentration dependent inhibition by puerarin upon IKs at the peak currents and tail currents 
were show in Fig. 4c. Dosage curve was fitted with non-linear Hill. IC50 = 55.63 μ M at the peak currents and 
IC50 = 59.75 μ M at the tail currents, Hill coefficient was 0.989. n = 6 each point.
The results above clearly suggested that puerarin inhibitory effect upon Kv7.1 and IKs was in the range of 
micromolar concentration, which was achievable in clinic application. Inhibitory effects of puerarin upon Kir2.1 
Figure 3. Puerarin inhibited Kv7.1 channels in a dosage dependent manner. (a) Puerarin at the concentrations 
of 10 μ M, 100 μ M, 1 mM and10 mM significantly inhibited Kv7.1 currents illustrated by the protocol of voltage steps, 
respectively. (b) I-V curves summarized inhibitory effects of puerarin at concentrations of 10 μ M, 100 μ M, 1 mM, 
10 mM and recovery after compound wash off. Different concentrations of puerarin decreased the Kv7.1 from 
(24.3 ± 1.1) pA/pF to (19.1 ± 1.0) pA/pF, (7.9 ± 0.8) pA/pF, (6.1 ± 0.4) pA/pF, (4.8 ± 0.8) pA/pF, and decreased the 
Kv7.1-tail current from (10.4 ± 0.6) pA/pF to (8.8 ± 0.7) pA/pF, (3.8 ± 0.6) pA/pF, (2.5 ± 0.9) pA/pF, (2.0 ± 0.5) pA/
pF at 40 mV, respectively. (c) Concentration dependent inhibition by puerarin upon Kv7.1 at the peak currents and 
tail currents. Dosage curve was fitted with non-linear Hill. IC50 = 36.01 μ M at the peak currents and IC50 = 39.77 μ M 
at the tail currents, Hill coefficient is 0.997. n = 6 each point.
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and Kir 2.3 required a concentration in hundreds millimolar and it was rare in clinic application. The following 
mechanism study was then focused on the Kv7.1 and IKs.
Puerarin might inhibit the current of Kv7.1/IKs in a PKA-independent pathway. It is well known the 
activation of G protein-coupled receptors (GPCR) could augment Kv7.1 and IKs via a PKA pathway28. Isoproterenol 
was an agonist of β 1 receptor which couples with GPCR29. Application of isoproterenol activated adenylyl cyclase 
which producted cAMP. Alternatively, forskolin activated adenylyl cyclase directly to generate cAMP30. Application 
of isoproterenol, forskolin and 8-Br-cAMP consistently augmented Kv7.1 and IKs current in HEK293 cells 
(Fig. 5a–c). Puerarin reversed these augment effects and furtherly inhibited Kv7.1 currents (Fig. 5a–c). The addi-
tional results revealled that puerarin at the concentration of 1 mM had no effect on intracellular cAMP concentration 
both in HEK293 transfected Kv7.1/IKs channel and in rat cardiac myocytes (Fig. 5d). Suggesting that puerarin had 
no effect upon the increase of cAMP induced by isoproterenol and forskolin. In addition, we confirmed the results in 
the rat ventricular myocytes that puerarin significantly inhibited IKs despite pharmacological activation of PKA with 
forskolin (Fig. 5e,f). Overall, these results partly illustrated that puerarin might inhibit the current of Kv7.1/IKs in a 
PKA-independent manner and suggested puerarin might principally and directly inhibit channels.
Puerarin might directly inhibit Kv7.1 and IKs channels. In the inside-out recording model, puerarin 
was applied directly to the intracellular side of ion channels and dissociated of puerarin in activities due to cellular 
barrier limitations. Single channel currents of Kv7.1 possessed the conductance of 4.4 pS elicited at the different 
voltages (Fig. 6a). The open probability of Kv7.1 channel was significantly reduced by puerarin at the concentra-
tion of 100 μ M, which was further abolished by a specific antagonist of Kv7.1, 293B (Fig. 6b).
Single channel currents of IKs possessed the conductance of 15.9 pS elicited at the different voltages (Fig. 6c). 
The open probability of IKs channel was also reduced by puerarin at the concentration of 100 μ M significantly, 
which was also further abolished by a specific antagonist of IKs, 293B (Fig. 6d).
Baicalin inhibited Kir 2.1 channels, whereas enhanced IKs channels in a dosage dependent 
manner. Baicalin was known as a flavone (Fig. 7e) and was found in plants as scutellaria baicalensis31 and 
herbs as HUANGQIN32. In contrast to puerarin, Baicalin at the concentrations of 1 mM significantly inhibited 
Kir2.1 currents illustrated by the ramp voltage protocol, and this effect could be reversed by washing-off compound 
(Fig. 7a). There is a concentration dependent inhibition by baicalin upon Kir 2.1. The maximal inhibitory effect 
was (40.95 ± 2.05) % and saturation dosage was 50 mM. Dosage curve was fitted with non-linear Hill. IC50 = 8.02 μ 
M, Hill coefficient is 0.983 (n = 5 each point) (Fig. 7b). In addition, baicalin at the concentrations of 100 μ M sig-
nificantly increased IKs illustrated by the voltage steps protocol (Fig. 7c), and this effect could be reversed by 
Figure 4. Puerarin inhibited IKs channels in a dosage dependent manner. (a) Puerarin at the concentrations 
of 10 μ M, 100 μ M, 1 mM and10 mM significantly inhibited IKs currents illustrated by the protocol of voltage steps, 
respectively. (b) I-V curves summarized inhibitory effects of puerarin at concentrations of 10 μ M, 100 μ M,  
1 mM, 10 mM and recovery after compound wash off. Different concentrations of puerarin decreased the IKs 
from (33.8 ± 3.2) pA/pF to (25.6 ± 2.4) pA/pF, (15.7 ± 1.9) pA/pF, (6.0 ± 1.3) pA/pF, (5.4 ± 1.7) pA/pF, and 
decreased the IKs-tail current from (23.5 ± 1.2) pA/pF to (17.8 ± 1.5) pA/pF, (9.7 ± 1.1) pA/pF, (6.4 ± 1.2) pA/pF, 
(5.2 ± 1.3) pA/pF at 40 mV, respectively. (c) Concentration dependent inhibition by puerarin upon IKs at the peak 
currents and tail currents. Dosage curve was fitted with non-linear Hill. IC50 = 55.63 μ M at the peak currents and 
IC50 = 59.75 μ M at the tail currents, Hill coefficient is 0.989. n = 6 each point.
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washing-off compound (data not shown). There was a concentration dependent enhancement by baicalin upon IKs 
currents. The maximal increased effect was (57.32 ± 3.07) % and saturation dosage was 1 mM. Dosage curve was 
fitted with non-linear Hill. EC50 = 137.95 μ M, Hill coefficient was 0.993 (n = 5 each point) (Fig. 7d).
Discussion
In this study, puerarin significantly prolonged ventricular APD when the concentration as low as micromolar 
range and exhibited a dosage dependent inhibitory manner. However, submicromolar puerarin had no effect 
on resting RMP, APA and Vmax of action potential. Only above the concentration of 10 mM, Puerarin exhib-
ited more aggressive effect on action potential, and shifted RMP to the positive direction. In addition, as low as 
micromolar range of concentrations, puerarin significantly inhibited Kv7.1 and IKs. These inhibitory effects were 
due to the directly inhibition of puerarin upon channels rather than the PKA pathway. In the millimolar range of 
Figure 5. Puerarin might inhibit the current of Kv7.1/IKs in a PKA-independent pathway. (a) Isoproterenol 
significantly enhanced Kv7.1 current whereas puerarin (100 μ M) antagonized such activation effect. (b) Forskolin 
significantly enhanced Kv7.1 current whereas puerarin (100 μ M) antagonized such activation effect. (c) 8-Br-cAMP 
significantly enhanced Kv7.1 current whereas puerarin (100 μ M) antagonized such activation effect. (d) 1 mM 
puerarin had no effect on intracellular cAMP concentration and no effect upon the increase of cAMP induced by 
isoproterenol, forskolin in rat cardiac myocytes. (e) forskolin significantly enhanced IKs current whereas puerarin 
(100 μ M) antagonized such activation effect in rat cardiac myocytes. (f ) Statistical analysis of Fig. 5e.
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Figure 6. Puerarin might directly inhibited Kv7.1 and IKs channels. (a) Single channel currents with the 
conductance of 4.4 pS elicited at the different voltages. (b) The open probability of Kv7.1 channel was reduced by 
puerarin at the concentration of 100 μ M significantly, which was further abolished by the specific antagonist of 
Kv7.1, 293B. (c) Single channel currents with the conductance of 15.9 pS elicited at the different voltages.  
(d) The open probability of IKs channel was reduced by puerarin at the concentration of 100 μ M significantly, 
which was further abolished by the specific antagonist of IKs, 293B.
Figure 7. Baicalin inhibited Kir 2.1 channels and enhanced IKs channels in a dosage dependent manner. 
(a) Baicalin at the concentrations of 1 mM significantly inhibited Kir2.1 currents illustrated by the ramp voltage 
protocol. This effect could be partly reversed by simple compound wash-off. (b) Concentration dependent 
inhibition by baicalin upon Kir 2.1. The maximal inhibitory effect was (40.95 ± 2.05) % and saturation dosage 
was 1 mM. Dosage curve was fitted with non-linear Hill. IC50 = 8.02 μ M, Hill coefficient is 0.983. n = 5 each 
point. (c) Baicalin at the concentrations of 100 μ M significantly enhanced IKs currents illustrated by the 
protocol of voltage steps, respectively. (d) Concentration dependent enhancement by baicalin upon IKs 
currents. The maximal increased effect was (57.32 ± 3.07) % and saturation dosage was 1 mM. Dosage curve was 
fitted with non-linear Hill. EC50 = 137.95 μ M at the peak currents, Hill coefficient is 0.993. n = 6 each point. (e) 
The molecular structural formula of baicalin.
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concentrations, puerarin significantly inhibited inward rectified K+ channels, and exhibited bigger effect upon 
Kir2.1 vs Kir 2.3. These results provided direct evidence and mechanism that puerarin prolonged APD majorly 
via its inhibitory effect upon Kv7.1 and IKs, supporting the widely clinical application of puerarin in treatment of 
cardiovascular diseases.
We also demonstrated that puerarin could reverse 10 nM ISO-mediated AP shortening on rat ventricular 
myocytes. Besides this cellular model of arrhythmia, several studies had announced puerarin could accelerate 
cardiac angiogenesis and improve cardiac function of myocardial infarction rats by upregulating VEGFA, Ang-1 
and Ang-233. Another study demonstrated that puerarin improved cardiac function after MI in diabetic mice 
through increasing the expression and translocation of GLU4 while attenuating the expression and translocation 
of CD3634.
In addition to previous studies, which suggested that puerarin affected calcium-activated potassium chan-
nels35 and fast Na+ channels12, our results revealed that puerarin significantly influences Kv7.1, IKs and IK1. 
According to the change of action potential by puerarin, the extension of APD majorly contributed to its pharma-
cology perspectives. Although puerarin exerted inhibitory effects upon Kir2.1, Kir2.3, Kv7.1 and IKs, it exhibited 
distinct effective dosage, IC50 and saturation. At a micromolar concentration, puerarin inhibited KvLQT1 and IKs 
and when application of milimolar puerarin, it affected Kir2.1, Kir2.3, KvLQT1 and IKs. Prolonged APD played a 
key role in slowing down heart rate and lengthening the refractory period of myocytes, these results might explain 
possible mechanism of action in the treatment of arrhythmia. Very recent comprehensive analysis of regional ion 
channel expression in normal and myopathic hearts documented that the ratio among Kir2.1, Kir2.2 and Kir2.3 
was roughly around 13:7:8 in normal left ventricles and around 16:5:13 in myopathic left ventricles36. Such similar 
alternations in expression of KV7.1/IKs in the procession of myopathic path might also occur, illustrating distinct 
pharmacology effects of puerarin in different ion channel expression profiles in this physiol-pathological process. 
In different patients, puerarin might exhibit different treatment efficiency due to the cardiac profiles with different 
ion channel composition.
In the heart, IKs had an important role in cardiac action potential repolarization37. IKs contributed little to the 
ventricular action potential repolarization under normal circumstances38. However, IKs was markedly improved 
when ventricular repolarization faced challenging conditions, such as increased sympathetic tone. The slow acti-
vation and deactivation kinetics led to accumulation of IKs, maintaining channel open state. Thus, under chal-
lenging situations, IKs prevented excessive action potential prolongation and development of arrhythmogenic 
early afterdepolarization by providing a repolarization reserve39,40.
To date, nearly three hundred mutations in KCNQ1 and at least 20 mutations in KCNE1 have been identified, 
casing long QT syndrome (LQT), short QT syndrome (SQT), sinus bradycardia and atrial fibrillation (AF)41. Most 
of the mutations caused a loss of function of KCNQ1 and KCNE1, resulting in LQTS1 and LQT5 syndrome, an 
inherited disorder characterized by a delayed ventricular repolarization, syncope and sudden death42. However, 
a few gain-of-function mutations identified in KCNQ1 and KCNE1 were associated with atrial fibrillation and/
or the SQT syndrome43. Although it still remains unclear puerarin affects the conclusive domain or binding site 
of the channels (such as basolateral targeting signal, PKA phosphorylation site and A-kinase anchoring protein 
binding), we are aware that further site-mutation studies of vital domain or binding site are needed to reveal the 
underlining mechanism. In this study, our results partly revealed that puerarin probably inhibit KCNQ1 and IKs 
via direct inhibition, as puerarin was applied directly to the intracellular side and reduced the open probability of 
the channels under the inside-out recording model. Modulation of KCNQ1 and KCNE1 might be the mechanism 
of puerarin in the clinic treatment of arrhythmia.
Our results were consistent to a previous study in the conclusion that puerarin could inhibit inward recti-
fied potassium channels44, but inconsistent with a different effective dosage range. This discrepancy was mainly 
attributed to the different components and expressions of ionic currents in interspecies in ventricular myocytes. 
Besides, rat ventricular action potentials were considerably shorter in duration than that of guinea pig, which had 
a well-defined plateau phase. The rat ventricular myocytes exhibited a large initial phase of repolarization which 
was rapid at depolarized potentials, and was slower at negative potentials45. In our system, expression systems 
were employed to simplify the condition and avoid the interference. Our results suggested that puerarin could 
affect inward potassium channels but in an extremely high dosage. Such dosage was rarely used in clinic. Kir2.3 
exhibited more sensitive to puerarin in contrast to Kir2.1, suggesting puerarin might compete with PIP2 to bind 
with Kir.
Interestingly, baicalin is a flavone, an analog of puerarin but extracted from another Chinese medicinal herb 
named Scutellaria baicalensis32. In a similar concentration range, Baicalin was found to inhibit Kir2.1 but aug-
ment IKs (Fig. 7). Such distinct effects reflected their different clinic results and vivided pharmacological effects 
from herbs. A recent study46 revealed the effect of baicalin on producing mesenteric arteries relaxation by acti-
vating large-conductance Ca2+ -activated K+ channel (BK(Ca)) and inhibiting voltage-dependent Ca2+ channel 
(VDCC) in a concentration-dependent manner. The cGMP/PKG and cAMP/PKA pathways had been known in 
the regulation of these two channels. Therefore, further study was necessary to confirm the additional and dispa-
rate effect between puerarin and baicalin on cardiac arrhythmia.
In summary, the present study provides the novel inhibitory effect of puerarin on Kv7.1/IKs underlining the 
mechanism of extending APD and anti-arrhythmic activity. Puerarin may directly inhibit Kv7.1/IKs channel 
independent of PKA activation, and it certainly inhibits Kir2.1 and Kir2.3 channels in some extent, suggesting the 
rational and discreet application of puerarin in clinic treatment of cardiovascular diseases.
Methods
Chemicals. Puerarin was obtained from Beijing Saisheng Pharmaceutial Company (98.4% purity), taurine, 
K2-ATP, HEPES, EGTA, baicalin, isoproterenol, forskolin, the cAMP analog 8-Bromoadenosine-3′ , 5′ -cyclic 
monophosphorothioate were purchased from Sigma-Aldrich (St. Louis., MO, USA). Collagenase (type II) and 
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bovine serum albumin (BSA) were purchased from Invitrogen (Carlsbad, CA, USA). All other reagents were of 
analytical grade. All drugs and reagents were dissolved in distilled water unless otherwise noted. Isoproterenol 
(1 mM) was dissolved in 0.1% ascorbic acid in distilled water. Baicalin (10 mM), forskolin (100 mM) was dissolved 
in DMSO. Final DMSO concentrations did not exceed 0.1%.
Animal experiments. Fifty male Sprague-Dawley rats (10–12 weeks) were used for this experiment. 
Myocytes were prepared from ventricles by standard collagenase dissociation technique. All animals received 
humane care in compliance Guide for the Institutional Animal Care and Use Committee (IACUC) and was 
approved by the Ethics Review Board for Animal Studies of Institute of Molecular Medicine (IMM), Peking 
University). All methods were carried out in accordance with the approved guidelines.
Solutions. The Tyrode’s solution contained (mM): 126 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 0.33 NaH2PO4, 10 
HEPES and 10 glucose, pH 7.4 (adjusted with NaOH). The Ca2+-free Tyrode’s solution was prepared by removing 
CaCl2 from the Tyrode’s solution. The Kreb’s solution used for cell storage contained (mM): 70 glutamic acid, 30 
KCl, 15 taurine, 0.5 MgCl2, 10 KH2PO4, 0.5 EGTA, 10 HEPES, 10 glucose, and 1% albumin, pH 7.4 (adjusted with 
KOH). The enzyme solution used for the rat cardiomyocyte isolation contained 0.08 g/L collagenase (type II) and 
1.0 g/L BSA in Kreb’s solution. For action potential recording on cardiomyocyte, the pipette solution contained 
(mM): 100 potassium aspartate, 30 KCl, 1 MgCl2, 5 Mg-ATP, 5 EGTA, 5 HEPES, pH 7.3 (adjusted with KOH); 
the Tyrode’s solution was used as the standard bath solution. For whole-cell recording of IKs on myocytes, the 
pipette solution contained (mM): 125 potassium aspartate, 20 KCl, 1 MgCl2, 5 Mg-ATP, 10 EGTA, 5 HEPES, pH 
7.3 (adjusted with KOH); the bath solution contained (mM): 132 NaCl, 4 KCl, 1.8 CaCl2, 1.2 MgCl2, 10 HEPES, 
5 glucose, pH 7.4 (adjusted with NaOH). 3 μ M nifedipine and 5 μ M E-4031 were used to block the calcium current 
and IKr, respectively. For whole-cell recording on HEK-293 cells, the pipette solution contained (mM): 140 KCl, 
2 MgCl2, 10 HEPES, 0.1 EGTA, 4 K2-ATP, pH 7.3 (adjusted with KOH); the bath solution contained (mM): 
120 NaCl, 5 KCl, 1.5 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, pH 7.4 (adjusted with NaOH). For single-channel 
recording, the pipette solution (extracellular) contained (mM): 145 KCl, 10 HEPES, 10 glucose, pH 7.4 (adjusted 
with KOH); the bath solution (intracellular) contained (mM): 145 KCl, 1.2 MgCl2, 10 HEPES, 0.1 EGTA, pH 7.38 
(adjusted with KOH).
Cell preparations. Single ventricular myocytes were isolated from adult rat hearts via enzymatic dissociation 
as previously described47. Briefly, the rats were anesthetised with 25% chloral hydrate (0.1 g/100 g). Their hearts 
were excised rapidly and retrogradely perfused on a Langendorff apparatus with a Ca2+-free Tyrode’s solution 
for 5 min before the perfusate was switched to an enzymatic solution for 10–20 min. The perfusate was finally 
changed to Kreb’s solution for 5 min. The perfusates were bubbled with 95% O2 + 5% CO2 and maintained at 
37 °C. The ventricles w ere cut into small chunks and gently agitated in Kreb’s solution. The cells were filtered 
through nylon mesh (pore size 200 μ m) and stored in Kreb’s solution at 4 °C.
Recording of action potentials. Action potentials were elicited at 1 Hz by 2 ms current pulses applied 
using the patch pipette. The APD at 50% and 90% repolarization (APD50 and APD90), RMP, APA and Vmax were 
measured.
Whole cell patch clamp recording. Cell suspensions were transferred into a chamber on the stage of a 
Nikon Eclipse Ti inverted microscope (Tokyo, Japan). The whole-cell recordings were performed using isolated 
single ventricular myocytes. Patch electrodes were pulled from a horizontal microelectrode puller (P-1000, Sutter 
Instrument Co, USA) and fire polished to final tip resistance of 4.0–8.0 MΩ when filled with internal solutions. 
Signals were amplified with an Axopatch 200B amplifier (Axon Instruments, USA) and filtered at 1 kHz. The 
pCLAMP 9.0 software was used to generate current and voltage clamp protocols, acquire data, and analyse the 
current traces. The whole-cell series resistance was compensated to more than 80%. All of the experiments were 
performed at room temperature (22 ± 1 °C). The whole-cell IK1 was elicited by a ramp voltage protocol from 
− 140 to + 40 mV in 1 s, or at a 0 mV holding potential to test potentials from − 140 to + 40 mV in 10 mV incre-
ments. The IK1 was calculated as the difference between the peak inward current and the holding current level. 
The whole-cell Kv7.1/IKs were elicited from a − 30 mV holding potential to test potentials from − 80 to + 40 mV 
in 10 mV increments.
Single-channel inside-out patch clamp recording. Single-channel activity was recorded at a series of 
holding levels ranging from 10 mV of 50 mV. The data were acquired at 20 KHz and lowpass filtered at 5 kHz. 
During post-analysis, data were further filtered at 300 Hz. Single-channel events were listed and analysed by 
pclampfit 9.0 (single-channel search-in-analyse function). NPo, the product of the number of channels and the 
open probability, was used to measure the channel activity within a patch. In total, 50% threshold cross-method 
was used to determine valid channel openings. Initial (1–2 min) single-channel records were normally used as the 
control. The activity of Kv7.1/IKs during application of chemicals was normalized to activity during the control 
period to assess the effects of chemicals on Kv7.1/IKs activity.
cDNA constructs. Human Kir2.1 cDNA, Kir2.3 cDNA, Kv7.1 cDNA and KCNE1 cDNA, was cloned in 
Human Embryonic Kidney 293 cells, respectively. In some cases, Kv7.1 cDNA and KCNE1 cDNA were simulta-
neously cloned in Human Embryonic Kidney 293 cells.
All of the cDNAs above were confirmed with DNA sequencing (Majorbio, Shanghai, China).
Mouse/Rat cAMP assay. cAMP levels were measured in rat cardiomyocytes using a Mouse/Rat cAMP kit 
(cAMP parameter assay kit, R&D Systems) according to the manufacturer’s instructions. The assay is based on the 
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competitive binding technique. A streptavidin-coated plate is incubated with a biotinylated monoclonal antibody 
specific for cAMP. Following a wash to remove excess monoclonal antibody, cAMP present in a sample competes 
with a fixed amount of horseradish peroxidase (HRP)-labeled cAMP for sites on the monoclonal antibody. This is 
followed by another wash to remove excess conjugate and unbound sample. A substrate solution is added to the 
wells to determine the bound enzyme activity. The color development is stopped and the absorbance is read at 
450 nm. The intensity of the color is inversely proportional to the concentration of cAMP in the sample. The level 
of cAMP in the sample was determined based on a standard curve and expressed as pmol/mg per each sample. 
Normalized cAMP was calculated by compared with the control group. In our study, we investigate the effect of 
puerarin on intracellular cAMP concentration and its effect upon the increase of cAMP induced by isoproterenol, 
forskolin and 8-Br-cAMP.
Statistics. The data were presented as the Mean ± SD. Dosage curves were fitted with pCLAMP 9.0 (Axon 
Instruments) and software Origin 7.0 (OriginLab, USA). The statistical significance was determined using a t-test 
when comparing two groups and ANOVA when comparing multiple groups. A value of P < 0.05 was considered 
statistically significant.
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